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Abstract
Type 1 interferons such as interferon-alpha (IFNα) inhibit replication of Human immunodefi-
ciency virus (HIV-1) by upregulating the expression of genes that interfere with specific
steps in the viral life cycle. This pathway thus represents a potential target for immune-
based therapies that can alter the dynamics of host-virus interactions to benefit the host. To
obtain a deeper mechanistic understanding of how IFNα impacts spreading HIV-1 infection,
we modeled the interaction of HIV-1 with CD4 T cells and IFNα as a dynamical system. This
model was then tested using experimental data from a cell culture model of spreading HIV-
1 infection. We found that a model in which IFNα induces reversible cellular states that
block both early and late stages of HIV-1 infection, combined with a saturating rate of con-
version to these states, was able to successfully fit the experimental dataset. Sensitivity
analysis showed that the potency of inhibition by IFNα was particularly dependent on spe-
cific network parameters and rate constants. This model will be useful for designing new
therapies targeting the IFNα network in HIV-1-infected individuals, as well as potentially
serving as a template for understanding the interaction of IFNα with other viruses.
Introduction
Around 65 million people worldwide have been infected with Human immunodeficiency virus
(HIV-1) [1]. Although progress has been made in mitigating disease with antiviral chemother-
apy, a protective vaccine has proved elusive, and other approaches are still needed. Further-
more, permanently eliminating virus from patients undergoing therapy has been difficult due
to the existence of latently infected reservoirs that are resistant to standard antiviral therapy
[2]. Another possible approach to treating HIV-1 infection is to alter aspects of virus-host
dynamics by targeting host pathways that inhibit or enhance infection. For this to be successful,
a deep understanding of the dynamics underlying how specific host pathways interact with
HIV-1 will likely be required.
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The application of mathematical modeling to HIV-1 dynamics during acute and chronic
infection has been highly successful at improving our understanding of the basic features
of clinical infection. In particular, fundamental insights into the response to antiviral
therapy, and the existence of multiple long-lived virus reservoirs have been revealed [3–6]. In
early models, the extent of infection was typically limited by target cell abundance, although
more recent HIV-1 models have also considered the impact of virus-specific CD8 T cells
[7,8]. However these models have not yet included the impact of the host innate immune
system.
A key component of the host innate response to HIV-1 infection is the type 1 interferon
(IFN) system [9,10]. In humans, type 1 IFNs consist of a family of related cytokines including
13 subtypes of IFNα, and two subtypes of IFNβ, that are secreted in response to stimulation of
microbe-sensing pattern-recognition receptors such as Toll-like receptors (TLRs), RIG-I-like
receptors (RLRs) and NOD-like receptors (NLRs) [11]. Type 1 IFNs bind the IFNα receptor
(IFNAR) and activate phosphorylation of the signaling molecules STAT1 and STAT2, which
then bind to Interferon regulatory factor 9 (IRF9) to form the Interferon-stimulated gene factor
3 (ISGF3) complex [12]. ISGF3 then binds to conserved Interferon-sensitive response elements
(ISREs) found upstream of interferon-sensitive genes (ISGs) [13]. Dozens of ISGs are upregu-
lated by IFNα, the function of which only a few are clearly understood [14]. Overall, IFNs cre-
ate an antiviral state that can either prevent de novo infections, or inhibit later stages of virus
replication in cells, such as assembly and egress.
IFNα is detectable in the plasma during acute HIV-1 infection, and this cytokine is predom-
inantly secreted by plasmacytoid dendritic cells (pDCs). pDCs detect HIV-1 via the single-
stranded RNA sensor TLR7, and secrete high levels of IFNα due to constitutive expression of
the Interferon regulatory factor 7 (IRF7) transcription factor [15,16]. A number of ISGs have
been shown to have anti-HIV-1 activity [17]. In particular, Myxovirus resistance protein 2
(MX2) inhibits early stages of infection [18], while other ISGs such as Apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), Tripartite motif-contain-
ing 22 (TRIM22) and Tetherin target later stages of infection, such as virus release or the infec-
tivity of virus particles [19–21]. Furthermore, IFNα inhibits HIV-1 replication in tissue culture
and blockade of IFNα during Simian immunodeficiency virus (SIV) infection leads to higher
virus levels in vivo [10].
Due to its HIV-1-inhibiting properties, IFNα has attracted interest as a therapeutic
target for HIV-1 infection. However, treatment of HIV-1 patients with recombinant IFNα
has produced inconsistent and disappointing results, with only modest effects on virus
levels being observed [22–24]. However, since the structure of the IFNα inhibitory network,
as well as the parameters that regulate its activity, are poorly understood, a better under-
standing of the underlying dynamics of this response may lead to improved and more
effective IFNα-based therapies. For example, dynamical models may help pinpoint which
molecular components of the IFNα inhibition network will achieve the most potent or most
durable results. Furthermore, modeling approaches have previously been applied to the
interaction of Hepatitis C virus (HCV) with pegylated IFNα, and have yielded valuable
insights [25–27].
To achieve this goal, we simulated the inhibition of HIV-1 by IFNα using a dynamical sys-
tem modeling approach, and tested this model in a well-defined experimental system. In our
model, IFNα interacts with both HIV-1-infected and uninfected cells to induce a reversible
state of blocked infection, and we demonstrate that this model makes testable predictions
about how specific network parameters may be targeted to achieve maximal inhibition of
HIV-1.
A Computational Model of Inhibition of HIV-1 by Interferon-Alpha
PLOS ONE | DOI:10.1371/journal.pone.0152316 March 24, 2016 2 / 16
Results
IFNα inhibits spreading HIV-1 infection
To generate an experimental dataset against which different models can be tested, we per-
formed experiments with a tissue culture model of spreading HIV-1 infection. CEM-5.25 cells
are a human CD4 T cell line that are susceptible to HIV-1 infection and contain an integrated
HIV-1 Long terminal repeat-Green fluorescent protein (LTR-GFP) reporter cassette [28].
Infected cells express GFP due to the viral Tat protein permitting transcription of GFP from
the integrated LTR. This allows us to distinguish HIV-1-infected cells (GFP+) from uninfected
cells (GFP-). CEM-5.25 cells were infected with HIV-1, and both cell and supernatant samples
were then isolated at 24h intervals for 72h post infection. Cells samples were analyzed by flow
cytometry to determine 1) absolute cell numbers and 2) the percentage of HIV-1-infected (%
GFP+) cells. Infectious virus in the supernatant was quantified by focus-forming assay using
GHOST-X4 reporter cells [29]. In infected cell cultures, the percent GFP+ cells, as well as the
concentration of infectious HIV-1 in the supernatant, rises exponentially until 3dpi (Fig 1B
and 1C). By day 3, total cell levels decline due to infection-induced cytopathic effect (Fig 1A).
To examine the effect of IFNα on the replication of HIV-1 in this system, different concen-
trations of IFNα were included in the tissue culture media from 6h prior to infection and
Fig 1. Inhibition of spreading HIV-1 infection by IFNα. A human CD4 T cell line was infected with HIV-1 and the total concentration of cells (A), the
proportion of infected (GFP+) cells (B), and the concentration of infectious virus in the supernatant (C), were monitored at 24h intervals. Different
concentrations of IFNα were added to the cells at 6h prior to infection, and the effect on total cell concentration (D), the percent infected cells (E), and the
concentration of infectious HIV-1 in the supernatant (F), were measured at 24h intervals (only 3dpi data shown). Measurements were taken in quadruplicate
and data shown are representative of three independent experiments. Error bars represent the standard deviation of the dataset.
doi:10.1371/journal.pone.0152316.g001
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maintained throughout the course of the infection. Inclusion of IFNα in the media caused a
clear and progressive decrease in the accumulation of infected cells (Fig 1E) and infectious
HIV-1 in the supernatant (Fig 1F), as well and an increase in overall cell density at later time-
points (Fig 1D). Interestingly, inhibition of HIV-1 by IFNα exhibits two key features–firstly
that the inhibition curve is very broad–with differential inhibition being observed for IFNα
concentrations over several orders of magnitude (from 2pg/mL to 20ng/mL), and secondly,
that inhibition of HIV-1 increased only minimally above 2ng/mL, suggesting that inhibition
saturates at higher IFNα concentrations. 50% inhibition of infection, as measured by infectious
HIV-1 concentration at 3dpi, was achieved between at 0.02ng/mL and 0.2ng/mL (Fig 1F).
Model of IFNα inhibitory network
We constructed a dynamical system that models the dynamics of CD4 T cells and their interac-
tion with both HIV-1 and IFNα (Fig 2, Table 1). This model shares a number of features with a
model previously used to analyze the IFNα response to influenza infection [30]. In this system,
the initial species are HIV-1 (H), CD4 T cells (C) and IFNα (I). HIV-1 can infect CD4 T cells to
generate infected cells (CH) at a rate proportional to the concentrations of HIV-1 and CD4 T
cells, via the infection rate constant (k5). Infected cells secrete infectious HIV-1 (H) at a constant
rate (k6). IFNα can bind to uninfected (C) or infected cells (CH) and convert them into refrac-
tory cells (CI) that cannot be infected, or infected-inhibited cells (CHI) that no longer release
virus, respectively. The rate of this conversion is determined by the concentrations of susceptible
cells and IFNα, as well as the k2 and k8 rate constants. Since the effects of IFNα on cells are
reversible, CI and CHI revert at an intrinsic rate (k3) to C or CH respectively. H and I each have
their own intrinsic decay rates that were measured separately (k7 and k9) (S1 Fig). Similar to pre-
vious models, consumption of virus by infected and uninfected cells is considered to be negligible
[6]. For these studies, an immortalized CD4 T cell line (CEM 5.25) was used that divides contin-
uously and has an intrinsic death rate that is negligible when maintained at subconfluency. By
contrast, HIV-1-infected cells (CH and CHI) cells die at an intrinsic rate due to the cytopathic
Fig 2. Model of inhibition of HIV-1 by IFNα. CD4 T cells are replenished at a rate proportional to the number
of cells, leading to exponential growth (k1). HIV-1 particles infect cells (k5), and infected cells die at an
inherent rate (k4). IFNα inhibits infection by converting uninfected cells (C) and infected cells (CH) into states
in which they cannot be infected (CI), or which no longer release infectious virus (CHI) (k2), and this rate is
also governed by a saturating rate constant (k8). Both these states are reversible, and without continued IFNα
exposure, CI and CHI revert to C and CH respectively (k3). Infected cells (CH) secrete HIV-1 at a continuous
rate (k6). Both HIV-1 and IFNα have their own natural decay rates (k7 and k9 respectively).
doi:10.1371/journal.pone.0152316.g002
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effect of HIV-1 infection (k4). All CD4 T cell subsets divide at an intrinsic rate to generate addi-
tional cells of the same type. The replenishment rate of all CD4 T cells was modeled with the
same rate for all subspecies (k1), which was experimentally determined by parameter fitting.
One key element of our model was the inclusion of a Michaelis-Menten saturating rate con-
stant (k8) for the conversion of C to CI and CH to CHI. As such, the conversion rate of C to CI
and CH to CHI saturates for high I concentrations, due to k8. Previous models of IFNα interac-
tion with virus infection do not include saturation for conversion to an inhibited state [30],
and this therefore represents a novel feature of this model.
Our system of equations is thus:
dCðtÞ
dt






























C Uninfected CD4 T cells cells uL-1
CI Uninfected CD4 T cells made refractory to infection by
IFNα
cells uL-1
CH HIV-1-infected CD4 T cells cells uL-1
CHI HIV-1-infected CD4 T cells in which virus release has been
blocked by IFNα
cells uL-1
H HIV-1 Focus-forming units
(FFU) uL-1
I Interferon alpha ng mL-1
k1 Intrinsic division rate of CD4 T cells day
-1
k2 Rate of conversion of CD4 T cells to refractory (CI) or
blocked (CHI) state
ng-1 day-1
k3 Intrinsic rate of reversion of IFNα exposed cells to HIV-1
susceptible state
day-1
k4 Death rate for HIV-1 infected cells (CH and CHI) day
-1
k5 Infection rate uL day
-1 FFU-1
k6 HIV-1 secretion rate from infected cells (CH) FFU cell
-1 day-1
k7 HIV-1 decay rate day
-1
k8 Saturated rate of conversion to CI or CHI ng mL
-1
k9 IFNα activity decay rate day
-1
doi:10.1371/journal.pone.0152316.t001
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Derivation of parameter estimates
First, the biological decay rates for HIV-1 (k7) and IFNα (k9) were experimentally determined
separately and assumed to be invariant in the different conditions (S1 Fig). Interestingly,
IFNα was found to have a decay rate that was negligible over the timescale studied in these
experiments, indicating that its biological activity is relatively stable in tissue culture media,
both in the presence and absence of cells (S1 Fig). We then estimated all seven remaining
parameters (k1 through k6 and k8) and the initial CD4 T cell count C(0) using the 72h time-
course data. In particular, we estimated these parameters by minimizing the weighted sum of
squared distances between each observation and the corresponding model prediction. Using
our experimental data, we cannot directly distinguish between individual uninfected subspe-
cies (C and CI) or infected subspecies (CH and CHI). Thus, the observed cell species, GFP
+ and GFP- cells, were assumed to represent the sum of CH and CHI, and the sum of C and
CI, respectively.
We compared the basic model (Model 1) to several variants of the model to determine
which could more accurately fit the dataset, and to identify the features that make important
contributions to model accuracy. For Models 1, 3 and 4, the rate of conversion to inhibited cell
states saturates due to the inclusion of the k8 rate constant, while for models 2, 5 and 6 we take
the conversion rate of C to CI and CH to CHI as linearly proportional to I, as has been done in
previous models of IFNα-virus interaction. For Model 3, cell division was restricted to unin-
fected CD4 T cells that had not been exposed to IFNα (C). For Model 4, we only considered
the interaction of IFNα with uninfected CD4 T cells, and ignored inhibition of previously
infected cells–meaning that the CHI species was eliminated from the model. For Model 5, the
death rate (k4) for the CHI species was modeled as distinct from the death rate of CH, while for
Model 6, the interconversion rate constants (k2 and k3) between uninhibited and inhibited
states were distinct for infected and uninfected cells. Different model configurations are
described graphically in S2 Fig.
The accuracy of the model fits was compared between these six different model configura-
tions (Table 2, S3 Fig). Notably, we found that inclusion of the saturation constant for IFNα-
mediated inhibition dramatically improved the accuracy of the fitting, with significantly lower
fit error for all model variants with saturating inhibition (Models 1, 3 and 4). Model 1 most
accurately simulated overall timecourse data, and became our default model for further analy-
sis. This model was also significantly superior to another variant with saturating inhibition that
lacks CHI (Model 4) suggesting that considering the effects of IFNα on infected cells is impor-
tant. Model 1 also accurately simulated important features of the timecourse data for %GFP-
and %GFP+ T cells, as well as the concentration of infectious HIV-1 in the supernatant (Fig 3).
The better fit for the saturating models was not simply due to the inclusion of an extra rate con-
stant (k8), because other variants of the linear inhibition model with additional parameters
(models 5 and 6) did not exhibit a comparable improvement in fit quality.
Estimated parameter values for the model rate constants were determined for all six model
variants (Table 3, Table A in S1 File). Estimates for many parameters were similar between
Model 1 (saturating) and Model 2 (linear). However, compared to Model 1, Model 2 exhibited
a significantly lower k2 estimate and a higher k3 estimate. The predicted concentrations for
each individual CD4 T cell subspecies were calculated from the best fit for both Model 1 and
Model 2. Notably, for most concentrations of IFNα, Model 1 predicts a higher proportion of
cells in the inhibited states compared to Model 2, although both models predict that the major-
ity of inhibited cells are uninfected over the range of IFNα concentrations tested (S4 Fig).
To further investigate the performance of our model, we re-plotted the data for HIV-1 levels,
percent GFP+ cells, and total cell concentration, at 3dpi, against different IFNα concentrations,
A Computational Model of Inhibition of HIV-1 by Interferon-Alpha
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and compared to model predictions (Fig 4). Significantly, Model 1 was able to simulate key fea-
tures of the HIV-1 inhibition curve accurately, including plateaus at high and low IFNα levels,
and a broadly sloped inhibitory curve. Furthermore, Model 1 performed better than a linear
inhibition model (Model 2) in two out of the three curves, with statistically significantly lower
RMSE values for HIV-1 concentrations and the percentage of infected cells.
To test whether our assumption of zero intrinsic decay for IFNα activity within our experi-
mental system affected the outcome of model fitting, we refitted the data with Model 1 and
Model 2 with the half-life of IFNα arbitrarily set to one day, and found that under these condi-
tions, Model 1 still dramatically outperformed Model 2 (Table B in S1 File). Also, we examined
whether consideration of HIV-1 consumption by cells affected model fitting, by including an
additional term to the HIV-1 decay rate equation, and determined that this had little impact on
model fit error (Table C in S1 File).
Differential effects of inhibitory parameters on the potency of IFNα
Using the saturating default model, we examined the sensitivity of biologically significant out-
comes of the model to specific parameters—particularly the parameters that regulated the
IFNα-related component of the network (k2, k3 and k8). To measure the outcome of parameter
scanning, we calculated the HIV-1 concentration at 3dpi as a function of IFNα concentration
with different parameter values over a range of 10 fold higher or lower than our estimated val-
ues. As expected, increasing the rate at which IFNα converts CD4 T cells to an inhibited state
(k2), and decreasing the reversion rate (k3), both individually resulted in lower total HIV-1
amounts at most concentrations of IFNα (Fig 5A). Modulating the saturation rate constant
(k8) had negligible effect on HIV-1 levels at higher IFNα concentrations, but modulated the
IFNα threshold at which saturation is achieved. Thus, although the inclusion of a saturation
constant greatly improved accuracy of the model, the outcome of infection is less sensitive to
the value of this parameter than for k2 and k3 at higher IFNα concentrations.
To describe the effects of IFNα on HIV-1, two metrics have previously been used–IC50, that
is, the IFNα concentration that results in 50% of maximal inhibition, and Vres, which is the
percent residual HIV-1 replication at the maximal IFNα concentration [31]. Based on our
Table 2. Sum of squared error for model fit versusmeasured species.
Model Description Parameters Fit
error
95% CI AIC
1 Basic model (saturating inhibition) 8 276.6 2502
2 Linear inhibition 7 882.4* 274.0–
1018.0
3712
3 Saturating inhibition, cell division restricted to C species 8 286.7 -13.4–35.7 2522
4 Saturating inhibition, no effect of IFNα on infected cells (no CHI) 8 298.7* 5.3–41.0 2547
5 Linear inhibition, separate death rates (k4) for CH and CHI 8 876.0* 270.0–
1012.9
3701
6 Linear inhibition, separate interconversion rates (k2 and k3) for uninfected (C and CI) and




A nonlinear least squares method was used to fit experimental data to six different model configurations–some with saturating inhibition by IFNα (Models
1, 3 and 4), and others with linear inhibition (Models 2, 5 and 6). Weighted squared error (Fit error) was determined for the best fit for each model with
respect to the all measured concentrations of GFP- cells, GFP+ cells, and HIV-1. Fit error total refers to the overall mean error of the fit to all collected
data. For each model, a 95% confidence interval for the increase in error over that of Model 1 (95% CI), and the Akaike Information Criterion (AIC), are
shown. An asterisk (*) next to the fit error value for a model indicates a statistically significant difference in performance relative to Model 1, at the p<0.05
level.
doi:10.1371/journal.pone.0152316.t002
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simulations, we observe a clear differential effect of k2, k3 and k8 on Vres, namely that k2 and k3
strongly affect Vres, while k8 does not (Fig 5B). Interestingly, increased k2 values and decreased
k3 values both reduced the IC50 of IFNα, while scaling these parameters in the opposite direc-
tion had little effect. By contrast, both higher and lower k8 values affected the IC50, with lower
k8 leading to a lower IC50, and higher k8 leading to a higher IC50. Overall, we conclude that Vres
is determined by the balance of k2 and k3, while IC50 is determined by the combined effect of
k2, k3 and k8. Thus our model makes testable predictions about how these specific network
parameters affect IFNα inhibition of HIV-1.
Fig 3. A saturatingmodel of inhibition of HIV-1 by IFNα recapitulates infection timecourse data.
Experimental data for the concentration of uninfected (GFP-) cells (A), infected (GFP+) cells (B), and
infectious HIV-1 (C) was fitted with a saturating model (Model 1). Open circles represent independent
experimental data points, while for each species, the solid black lines represent the model’s best fit. Data
points with the same value are shown side by side.
doi:10.1371/journal.pone.0152316.g003
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Discussion
In this manuscript we describe, for the first time, a dynamical model that simulates the interac-
tion of HIV-1 with IFNα, and demonstrate that this model accurately fits an experimental
dataset. Also, we have estimated rate constants for how IFNα interacts with CD4 T cells and
Table 3. Estimated model parameter values.
Parameter Units Model 1 value (95% CI) Model 2 value (95% CI)
k1 day-1 0.886 (0.820–0.930) 0.910 (0.842–0.956)
k2 ng-1 day-1 45.2 (39.8–52.3) 0.0763 (0.0544–0.1314)
k3 day-1 261 (9.2–338) 476 (0–29980)
k4 day-1 5.92 (4.65–7.29) 8.75 (6.87–10.78)
k5 uL day-1 FFU-1 0.00991 (0.00850–0.0115) 0.0177 (0.0147–0.0208)
k6 FFU cell-1 day-1 19.0 (18.1–20.0) 12.9 (11.7–13.6)
k8 ng mL-1 0.191 (0.082–0.411) NA
Values for unfixed rate constants were obtained from the best fits of Model 1 and Model 2 to the
experimental dataset.
doi:10.1371/journal.pone.0152316.t003
Fig 4. Saturating effect of IFNα on CD4 T cells improvesmodel accuracy. Dose-response data for the effect of different IFNα concentrations on the
concentration of HIV-1 (left panel), the percentage of GFP+ cells (middle panel), and on total cell concentration (right panel) at 3dpi were compared to model
generated estimates for Models 1 and 2. Root mean squared errors (RMSE) are shown on the figure panels. Circles represent individual data points. An
asterisk besides RMSE values for Model 2 denotes a statistically significant difference in performance relative to Model 1.
doi:10.1371/journal.pone.0152316.g004
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HIV-1, thereby providing a realistic range in which to perform simulations of infection. A key
novel feature of this model is a saturating rate constant for IFNα’s effects on target cells, which
significantly increased the accuracy of the model’s fit to the experimental data. In the absence
of this feature, the model performed poorly in fitting, and had a profoundly different balance
of forward and reverse rate constants for the generation of inhibited cellular states (k2 and k3).
Furthermore, we have found that a model in which IFNα affects both uninfected and infected
cells fit experimental data significantly better that one in which IFNα only affected uninfected
cells. Although the interaction of IFNα with viral infection has been previously studied using
modeling approaches [30,32–34], a saturating rate constant for inhibition of infection has not
been a standard assumption of these models. A similar study that considered inhibition of
influenza by IFNα found that a linear inhibition model, in which IFNα affects uninfected cells
Fig 5. Differential effects of inhibitory parameters of the potency of IFNα. (A) Experimentally measured values for k2 (left panel), k3 (middle panel) and k8
(right panel), were modulated up (blue) and down (red) by 10-fold, and the effect on the outcome of infection determined by running a simulation with these
parameter values substituted for the experimentally determined ones, and calculating the concentration of infectious HIV-1 at 3dpi. (B) The effect of
modulating values for k2, k3 and k8 on IC50 (concentration required for 50% inhibition) and Vres (the percent HIV-1 replication at maximal IFNα concentration)
were determined by scanning parameter values over a 10 fold range above and below our measured value, and calculating the HIV-1 concentration at 3dpi.
doi:10.1371/journal.pone.0152316.g005
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only, was able to successfully fit experimental data, suggesting that models of IFNα interaction
with viruses may require virus-specific dynamics [30].
This model could be useful for the design of novel therapies for HIV-1 that target the IFNα
pathway. Notably, our model recapitulates the observation that IFNα has a broad HIV-1-inhi-
bition curve, meaning that changes in IFNα concentration over several orders of magnitude
have only partial effects on HIV-1 levels. However, sensitivity analysis of the network rate con-
stants indicates that modulation of the k2 and k3 rate constants can lead to a dramatically more
potent inhibition of HIV-1 for a given IFNα concentration. By contrast, the value of the satura-
tion rate constant (k8) has a lesser effect on the course of infection for most IFNα concentra-
tions. As such, our model predicts that clinical modulation of k2 and k3 could prove more
beneficial than simply boosting total IFNα levels by a similar factor or by modulating k8.
In order to design therapies that can target the biological processes controlled by these rate
constants, it will be critical to identify the molecules that govern them. The signaling pathway
and transcriptional response to IFNα have been extensively characterized, and the identities of
many of the participating molecules have been described [14]. The rate of conversion to inhib-
ited states (k2) could reflect features such as the abundance of the IFNAR receptor, the expres-
sion level of IFNα signaling factors such as STAT1/2 and IRF9, as well as the transcription/
translation rate for antiviral effector proteins. The reversion rate (k3), by contrast, is likely
determined by the off-rate for ISGF3 detachment from the IRSE sequences in the promoters of
ISGs, and/or the degradation rate for antiviral effector proteins in the cytoplasm. The require-
ment for a saturating rate constant (k8) to accurately fit our dataset could reflect any rate-
limiting process in the generation of an ‘inhibited’ cell. Factors that contribute to these rate
constants could potentially be experimentally identified by manipulating expression of known
components of this pathway, and examining the impact on the network behavior. Novel thera-
pies designed to target these rate constants could involve boosting or reducing the expression/
activity of these key factors.
The application of this model to clinical data from HIV-1 patients could yield valuable
insights into HIV-1 immunity and pathogenesis. HIV-1 infection results in a wide range of
outcomes in terms of viral loads, immune responses, and disease progression. If parameter val-
ues can be derived for individual patients, these parameters could be examined for correlation
with any of these clinical outcomes. For example, do non-progressors and rapid progressors
have different parameter sets that can potentially contribute differences in the course of clinical
infection? Some evidence suggests that this may indeed be the case—females mount an intrinsi-
cally stronger IFNα response than males, and also exhibit stronger early control of HIV-1 [35–
38]. The dynamics of early acute HIV-1 infection, and the resulting innate immune response,
likely contains valuable information relating to the IFNα response of individual patients
that could be analyzed by a version of this model, but unfortunately, data from this phase of
infection have been difficult to obtain, since most patient are not diagnosed until they have
entered the chronic phase of infection.
An important consideration for IFNα-related therapy is that IFNαmay play different and
potentially opposing roles at different times during HIV-1 infection. Recent data suggest that
while IFNα and pDCs do indeed limit HIV-1/SIV levels during early infection, they may also
promote CD4 T cell depletion at later times, possibly due to IFNα-induced upregulation of
apoptosis [39]. However, administration of high doses of IFNα to SIV-infected African green
monkeys, which naturally tolerate infection, does not enhance CD4 T cell loss or pathogenesis
[40]. Furthermore, blockade of IFNα signaling in SIV-infected Rhesus Macaques leads to
higher viral loads and more rapid disease progression [10]. Therefore, it is unclear if future
models of IFNα’s role in clinical infection will have to incorporate this feature of IFNα’s behav-
ior in order to accurately model the disease process.
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Our model should also be considered in the light of some inherent caveats. For example, the
model relies on mass-action interactions to simulate the innate immune response to infection.
While this may accurately model responses in well-mixed compartments such as the blood, it
may not be applicable to immune responses in solid tissues such as lymph nodes or mucosal
surfaces. IFNαmay also have additional indirect mechanisms of influencing the course of
infection, such as helping to promote immune responses by Natural killer (NK) cells or lym-
phocytes [41,42]. Also, the results of this manuscript rely on an immortalized cell line that may
behave differently than primary human CD4 T cells in vivo. Furthermore, HIV-1 employs sev-
eral countermeasures against inhibitory ISGs, and different virus strains may exhibit differen-
tial sensitivity to IFNα [31].
Currently this model does not consider the contribution of endogenous IFNα to the course
of infection. In vivo, the endogenous IFNα response is driven by plasmacytoid DCs (pDCs),
and future development of this model to analyze clinical data from HIV-1 patients will likely
require the incorporation of pDCs and endogenous IFNα. Our model also makes several
assumptions that may not fully reflect details of HIV-1 infection, such as assuming that
infected and uninfected CD4 T cells have equivalent division rates. It is also likely that some
interferon-induced genes such as SCHLAFEN11 interfere with viral gene expression, which is
a mechanism not currently taken into account by our model [43]. Inhibition of viral transcrip-
tion or translation by IFNα would result in GFP- HIV-infected cells, which are indistinguish-
able from uninfected cells (C and CI) by the assays used in this study. As such our data may
underestimate the total number of HIV-infected cells in the presence of IFNα. Further studies
will be needed to determine the extent of this mechanism and its impact on modeling IFNα
and HIV-1.
Nevertheless, this study represents the first attempt to analyze the interaction of the innate
immune system with HIV-1 from a computational perspective, and demonstrates that quanti-
tative estimates for the parameters that regulate IFNα’s potency can be derived from experi-
mental data. As such, these findings should serve as a valuable starting point for future studies
investigating the dynamics of the host innate immune response to HIV-1.
Materials and Methods
Cells and viruses
CEM 5.25 cells and GHOST-X4 cells were obtained from Dan Littman (NYU) [28,44]. These
cells were maintained in RPMI or DMEMmedia respectively with 10% fetal calf serum, gluta-
mine, and penicillin/streptomycin. An integrated LTR-GFP cassette present in the genomic
DNA of these cells facilitates expression of Green Fluorescent Protein (GFP) upon HIV-1
infection.
The HIV-1 strain used was NL4-3, a CXCR4-tropic subtype B strain [44]. The pNL4-3 plas-
mid was obtained from aidsreagent.org. To generate stocks of infectious virus, 10ug of plasmid
was transfected into subconfluent 10cm plate of HEK-293FT cells (Invitrogen) using Mirus
LT-1 reagent (Mirus Bio). At 4hrs post-transfection, medium was replaced. At 2 days post-
transfection, the supernatant was harvested, clarified by low-speed centrifugation, then filtered
through 0.45uM filter. The samples were then aliquoted and frozen at -80C. The titer of the
stock was then determined by focus-forming assay.
For experimental infections, CEM-5.25 cultures were first exposed to IFNα for 6 hrs, then
infected with NL4-3 at a multiplicity of 0.1 focus-forming unit per cell for 1hr. The virus inocu-
lum was then removed and replaced with fresh media containing IFNα. The infected cells were
then plated in 96 well plates at approximately 100 cells/uL. At 24h intervals a small fraction of
the media (10%) was removed and replaced with media containing fresh IFNα.
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Focus forming assays
GHOST-X4 cells were plated at 10000 cells per well in a 96 well plate. A ten-fold dilution series
of each supernatant sample was made and 100ul of each dilution was used to innocculate
GHOST-X4 cells. At 3dpi, the supernatant was removed and the cells were fixed in 4% parafor-
maldehyde (PFA). The plate was then analyzed by fluorescence microscopy and the number of
GFP+ foci per well was counted. This was then used to calculate the concentration of focus-
forming units (FFU) per mL in each of the original supernatant samples.
Flow cytometry
Cell samples from infected CEM-5.25 cultures were fixed in 2% PFA for 20 minutes, then
diluted in phosphate buffered saline (PBS) and analyzed on an Accuri C6 flow cytometer. The
total concentration of CD4 T cells, and the percentage of infected cells (% GFP+), was calcu-
lated for each original sample.
Interferon
Human IFNα2a was obtained from Sigma Aldrich, reconstituted in PBS, and stored at -80C.
Computational analyses
Model fitting, simulation, and other computational analyses were done using the Python pro-
gramming language. The system of differential equations was integrated using SloppyCell [45].
Model fitting was done by solving a weighted nonlinear least squares problem. Let xijlt repre-
sent the data collected for species i at interferon level j, in replicate l at time point t. Let yijt(k)
be the corresponding model prediction for that species, interferon level, and time point, with














The measurement variance, σij
2, was estimated by first measuring the variance across repli-
cates at each time point, and then averaging these variances over time points. The nonlinear
squares problem was solved using random-restart optimization. For each random-restart run,
optimization was doing using the L-BFGS-B optimization routine [46,47]. Optimization was
started from 25 randomly selected initial values, and then the final parameters were chosen as
those that produced the lowest cost across all 25 runs.
Confidence intervals for the best-fit parameters were found using the profile likelihood
method [48]. The parameter confidence intervals reported here are simultaneous 95% confi-
dence intervals.
Model comparison was done using two complementary methods: AIC and nonparametric
confidence intervals on fit error. AIC provides a model comparison that incorporates the num-
ber of parameters, but requires assuming a normal noise model. Nonparametric confidence
intervals were estimated using the percentile bootstrap, so do not require any assumption
about the noise distribution. To determine if a difference in fit error between two models was
statistically significant at the p<0.05 level, 95% confidence intervals were computed for the dif-
ference in fit errors. If this 95% confidence interval contained zero, it indicated that the differ-
ence in model fit was not statistically significant at the 0.05 level. If the confidence interval
did not contain zero, it indicated that the difference in model fit was statistically significant.
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Supporting Information
S1 Fig. Calculation of decay rates for HIV-1 and IFNα.
(TIF)
S2 Fig. Alternative model configurations.
(TIF)
S3 Fig. Best fits for different model configurations.
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